CTAD highlights from 2023

Check out these highlights from the 2023 edition of the Clinical Trials in Alzheimer’s Disease (CTAD) conference which was held in Boston, USA from 24 to 27 October:

Phase 2 trial of ABvac40 vaccine reports positive results at CTAD, showing a robust immune response and potential cognitive benefits in very early AD

Biogen presents new findings of its Phase I study of BIIB080 in mild AD

Eisai plans to submit a biologics license application for a subcutaneous formulation of lecanemab to the FDA

Hummingbird Diagnostics presents its latest research at CTAD